International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework

Daniel C. Malone, Karl Claxton, Louis P. Garrison Jr., Maarten IJzerman, Kevin Marsh, Peter J. Neumann, Mark Sculpher, Adrian Towse, Carin Uyl-De Groot, Milton C. Weinstein

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Scopus)
71 Downloads (Pure)

Abstract

As members of the International Society for Pharmacoeconomics and Outcomes Research, we read with great interest the new American Society of Clinical Oncology (ASCO) conceptual framework to assess the value of cancer treatment options.1 We applaud the Value in Cancer Care Task Force for proposing a conceptual framework to support clinicians and patients in assessing the value of new cancer treatments. We acknowledge the challenges facing clinician–patient decision making, particularly concerning cancer treatments. Like ASCO, we recognize that the cost of treatments is increasingly being placed on patients through cost sharing and that engaging patients as part of making individual treatment decisions is of high importance. The ASCO framework highlights the growing tension among patients, insurance companies, and product manufacturers in a dynamic health care environment. In that light, the framework deserves a field test, and we look forward to seeing the outcome of that experience. We also appreciate the opportunity to offer comments and suggestions on the ASCO framework at this early stage, and our membership stands ready to support ASCO in future enhancements.
Original languageEnglish
Pages (from-to)2936-2937
JournalJournal of clinical oncology
Volume34
Issue number24
DOIs
Publication statusPublished - 2016

Keywords

  • METIS-317574
  • IR-100976

Fingerprint Dive into the research topics of 'International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework'. Together they form a unique fingerprint.

Cite this